Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.34 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | HRH2 | P25021 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11555941 | 0.87 | PKM (0.34) | PKMRXFP1CCNA2CDK2CCNA1 | |
| SCHEMBL16016862 | 0.84 | LMNA (0.41) | PKMRXFP1DYRK1APIM1CDK9 | |
| SCHEMBL9344676 | 0.84 | DYRK1A (0.34) | PKMRXFP1DYRK1APIM1CDK9 | |
| SCHEMBL16828162 | 0.80 | CCNA2 (0.50) | CCNA2CDK2CCNA1DYRK1A | |
| Hydrochloric Acid SCHEMBL16828222 | 0.78 | CCNA2 (0.48) | CCNA2CDK2CCNA1DYRK1A | |
| SCHEMBL5765829 | 0.78 | CYP1A2 (0.39) | CCNA2CDK2CCNA1HTTPOLB | |
| SCHEMBL9124920 | 0.76 | SMN1; SMN2 (0.36) | RXFP1HTTTDP1MAPTSMN1; SMN2 | |
| SCHEMBL6639436 | 0.76 | CYP1A2 (0.47) | CCNA2CDK2CCNA1LMNAALOX15 | |
| SCHEMBL3667991 | 0.75 | CCNA2 (0.34) | PKMRXFP1CCNA2CDK2CCNA1 | |
| SCHEMBL27365757 | 0.74 | CCNA2 (0.32) | CCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8901141-B2 | Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharmaceutical compositions containing them | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2014-12-02 | — | — | US | disclosed |
| EP-2240485-B1 | TRICYCLIC COMPOUNDS HAVING CORTICOTROPIN-RELEASING FACTOR ANTAGONISTIC ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | TAKEDA PHARMACEUTICAL (JP) | 2014-10-15 | — | — | EP | disclosed |
| US-8785460-B2 | Tricyclic compounds and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-22 | — | — | US | disclosed |
| CN-101981031-A | Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharmaceutical compositions containing them | TAKEDA PHARMACEUTICAL | 2011-02-23 | — | — | CN | disclosed |
| US-20100298287-A1 | TRICYCLIC COMPOUNDS HAVING CORTICOTROPIN-RELEASING FACTOR ANTAGONISTIC ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-25 | — | — | US | disclosed |
| EP-2240485-A1 | TRICYCLIC COMPOUNDS HAVING CORTICOTROPIN-RELEASING FACTOR ANTAGONISTIC ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Takeda Pharmaceutical Company Limited (JP) | 2010-10-20 | — | — | EP | disclosed |
| US-20090291915-A1 | Silicon Compounds and Their Use | TAKEDA CAMBRIDGE LIMITED (GB) | 2009-11-26 | — | — | US | disclosed |
| US-20090209522-A1 | Heterocyclic Non-Peptide GNRH Antagonists | TAKEDA CAMBRIDGE LIMITED (GB) | 2009-08-20 | — | — | US | disclosed |
| US-20090209522-A1 | Heterocyclic Non-Peptide GNRH Antagonists | TAKEDA CAMBRIDGE LIMITED (GB) | 2009-08-20 | — | — | US | disclosed |
| WO-2009093747-A1 | TRICYCLIC COMPOUNDS HAVING CORTICOTROPIN-RELEASING FACTOR ANTAGONISTIC ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-07-30 | — | — | WO | disclosed |
| US-20090186879-A1 | TRICYCLIC COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-07-23 | — | — | US | disclosed |
| US-20080261918-A1 | Silicon Compounds and Their Use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-23 | — | — | US | disclosed |
| US-20080261918-A1 | Silicon Compounds and Their Use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-23 | — | — | US | disclosed |
| US-5397781-A | Pyrimidine derivatives | MOCHIDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1995-03-14 | — | — | US | disclosed |
| EP-0561175-A1 | Pyrimidine derivatives and pharmaceutical compostions containing them | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1993-09-22 | — | — | EP | disclosed |
| EP-0019811-A1 | Pyrimidine compounds, process for their preparation, pharmaceutical compositions containing them and their therapeutical use | CIBA-GEIGY AG (CH) | 1980-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186879-A1 | TRICYCLIC COMPOUNDS AND USE THEREOF | CRHR1, CRHR2, HCRTR1 | PKM 2051/4885RXFP1 12/4885CCNA2 1443/4885 |
| US-20090209522-A1 | Heterocyclic Non-Peptide GNRH Antagonists | GNRHR, GHRHR, FSHR | PKM 3487/4885RXFP1 69/4885CCNA2 582/4885 |
| US-20080261918-A1 | Silicon Compounds and Their Use | SOST, SIK2, SCLY | PKM 1470/4885RXFP1 4233/4885CCNA2 1151/4885 |
| US-20090291915-A1 | Silicon Compounds and Their Use | SOST, SIK2, SIK3 | PKM 2477/4885RXFP1 4198/4885CCNA2 1579/4885 |
| US-20100298287-A1 | TRICYCLIC COMPOUNDS HAVING CORTICOTROPIN-RELEASING FACTOR ANTAGONISTIC ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CRH, CRHR1, CRHR2 | PKM 3081/4885RXFP1 28/4885CCNA2 1009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.